bevacizumab
roche
['sclc', 'lung', 'beva', 'bevacizumab', 'nsclc']
a randomized phase ii study comparing erlotinib with or without bevacizumab in patients with advanced non small cell lung cancer (nsclc) with egfr mutation: median pfs, 18.6 months vs 10.3 months; hr = 0.54 [95% ci, 0.31 0.95] #asco22 
Medicina Interna - Oncología Clínica - Profesor Titular @UPBColombia - Clínica Astorga. #Medellín / #Colombia mlujanonco@gmail.com #OncTwitter #Metaanalysis